Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Feb 28, 2014; 20(8): 1993-2004
Published online Feb 28, 2014. doi: 10.3748/wjg.v20.i8.1993
Published online Feb 28, 2014. doi: 10.3748/wjg.v20.i8.1993
Sequencing of treatment in metastatic colorectal cancer: Where to fit the target?
Sally Temraz, Deborah Mukherji, Ali Shamseddine, Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center (AUBMC), Riad El Solh 110 72020, Beirut, Lebanon
Author contributions: Temraz S, Mukherji D and Shamseddine A wrote this paper.
Correspondence to: Ali Shamseddine, MD, FRCP, Professor of Clinical Medicine, Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Box 11-0236, Riad El Solh 110 72020, Beirut, Lebanon. as04@aub.edu.lb
Telephone: +961-1-374374-5390 Fax: +961-1-370814
Received: September 25, 2013
Revised: December 1, 2013
Accepted: January 14, 2014
Published online: February 28, 2014
Processing time: 154 Days and 5.6 Hours
Revised: December 1, 2013
Accepted: January 14, 2014
Published online: February 28, 2014
Processing time: 154 Days and 5.6 Hours
Core Tip
Core tip: Metastatic colorectal cancer patients have many treatment options; however, the issue of best treatment sequence remains a challenge in this population. This review involves an in depth analysis of previous and most recent clinical advances in this field and aims to come out with treatment sequences that identify patient groups who are most likely to benefit from such sequences based on the current available data.